Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Migratory Polyarthritis as the Presenting Symptom of GPA

Adil Vural, MD, & Kinanah Yaseen, MD  |  Issue: May 2023  |  May 9, 2023

Paraneoplastic polyarthritis: A rare entity that has been described most in adenocarcinomas of the lungs and breasts, and as a hematological malignancy, paraneoplastic polyarthritis is characterized by migratory polyarthritis affecting primarily joints in the lower extremities, with the presence of RF and ANA in rare cases (20%).

Our patient was relatively young and had no constitutional symptoms or other symptoms concerning for indolent malignancy.13

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Diagnosis & Clinical Course

Plain films of our patient’s sacroiliac joints and lumbar spine were unremarkable. Hepatitis, tuberculosis, Lyme disease and parvovirus tests were negative. His uric acid level was within normal limits at 3.4 mg/dL (reference range: 4–8 mg/dL).

Based on his symptoms and the presence of RF, the leading diagnosis was palindromic rheumatism. The patient was scheduled for a follow-up visit in two weeks to discuss his diagnosis and start treatment.

FIGURE 2. Microscopic examination of the patient’s urine sample shows one red blood cell cast. (Click to enlarge.)

Repeat laboratory tests prior to initiation of methotrexate revealed acute elevation of creatinine at 3.4 mg/dL, compared with his previous baseline of 1.19 mg/dL. A urinalysis showed +3 hemoglobin and +3 protein. Urine sedimentation showed many red blood cell casts (see Figure 2).

He was admitted for evaluation of acute kidney failure. Laboratory tests during admission revealed the presence of C-ANCA and proteinase-3 antigen >8 (normal range < 1) and negative cryoglobulin and anti-glomerular basement membrane (GBM) antibodies.

Chest radiography was unrevealing, without hilar adenopathy. Computed tomography (CT) showed small subpleural nodules in the right lower and left upper lobes. CT of his sinus without contrast showed a clear mastoid and minimal mucosal thickening of the maxillary sinuses without acute sinusitis.

His ophthalmologic exam was consistent with episcleritis and possible mild anterior scleritis.

FIGURE 3. Kidney biopsy reveals pauci-immune necrotizing and crescentic glomerulonephritis. (Click to enlarge.)

He underwent right-sided kidney biopsy, and the pathology was consistent with pauci-immune necrotizing and crescentic glomerulonephritis with mild interstitial fibrosis (see Figure 3).

The patient was diagnosed with GPA and was administered pulse-dose methylprednisolone and four weekly infusions of rituximab in a dosage of 375 mg/m2 of body surface area.

Discussion

This case emphasizes the difficulties of early systemic vasculitides diagnosis and detection, which are always essential to avert serious morbidity and mortality.

AAV has a wide range of clinical manifestations, from single-organ limited to fulminant multi-system disease. Almost any organ can be affected, although the upper airways, lungs, kidneys, eyes and peripheral nerves are the most-often involved organs.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitiscase reportGranulomatosisgranulomatosis with polyangiitismigratory polyarthritis

Related Articles

    ANCA-Associated Vasculitis Trial Results May Change Standard of Care

    May 15, 2020

    SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient pop­ulation. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…

    Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly

    October 9, 2019

    NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…

    Trimethoprim-Sulfamethoxazole Prophylaxis Reduced Rituximab Infection Risk

    October 18, 2018

    Severe infections occurred in 25% of patients with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) who were treated with rituximab, according to results of an observational study conducted in the United Kingdom (U.K.) and Austria. Trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, however, reduced the risk of severe infections, the investigators reported in Annals of the Rheumatic Diseases.1 Andreas…

    ANCA Mortality: Are Patients Doing Better?

    December 13, 2019

    Patients with anti-neutrophil cytoplasmic antibody–associated vasculitides (AAV) have an increased risk of mortality. But treatments have evolved in recent years. Recent research found that between 1999 and 2017 the AAV mortality rate declined by nearly 2% per year in patients 65–74 years old…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences